0000950170-24-036398.txt : 20240326
0000950170-24-036398.hdr.sgml : 20240326
20240326160511
ACCESSION NUMBER: 0000950170-24-036398
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240322
FILED AS OF DATE: 20240326
DATE AS OF CHANGE: 20240326
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Curran Terrie
CENTRAL INDEX KEY: 0001690298
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 24783508
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 320 WEST 37TH STREET, 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
ownership.xml
4
X0508
4
2024-03-22
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001690298
Curran Terrie
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PARK
NJ
07932
true
true
false
false
President and Chief Executive
false
Common Stock
2024-03-22
4
S
false
16851
9.11
D
410784
D
Common Stock
3840.16
I
By 401(k)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.11 to $9.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes 1,604 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024.
Molly Henderson, Attorney-in-Fact for Terrie Curran
2024-03-26